Ample data in the literature indicate that Dll4 signaling plays a critical role in tumor angiogenesis and possibly in mediating resistance to anti-VEGF therapies, thus providing rationale for combined VEGF and Dll4 inhibition. This evidence concerns the gene DLL4 and neoplasm.